Fractional Exhaled Nitric Oxide (FeNO) in Biomass Smoke-Associated Chronic Obstructive Pulmonary Disease.


Journal

Medical sciences (Basel, Switzerland)
ISSN: 2076-3271
Titre abrégé: Med Sci (Basel)
Pays: Switzerland
ID NLM: 101629322

Informations de publication

Date de publication:
04 Oct 2024
Historique:
received: 21 08 2024
revised: 19 09 2024
accepted: 25 09 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by local and systemic inflammation independently of the risk factor; during the exacerbations, such inflammation is accentuated and amplified. A practical inflammatory marker and one with an applicable predictive value in the follow-up has been sought. FeNO has shown an excellent performance in that respect within the context of asthma and has also been studied in tobacco-smoke COPD (COPD-TS). In Biomass-smoke COPD (COPD-BS), this, to our knowledge, has not been evaluated. To measure FeNO levels in patients with COPD-BS and to compare these with those of patients with stable COPD-TS and in healthy controls. Transversal, observational, descriptive, comparative, and analytical study. A total of 57 patients, including 23 with COPD-BS, 17 with COPD-TS, and 17 healthy control subjects. The measurement of FeNO was carried out on all of these by means of the on-line chemiluminescence technique; the values were expressed in parts per billion (ppb) for their analysis. It was observed that the FeNO values were similar between COPD-BS and COPD-TS and were significantly different between the healthy and stable COPD (both groups). No correlation was found between pulmonary function and symptoms with FeNO in any of the groups. The level of FeNO in stable COPD is found to be increased in a similar manner in COPD-BS and COPD-TS, with a significant difference on comparing it with that of the healthy subjects.

Identifiants

pubmed: 39449408
pii: medsci12040052
doi: 10.3390/medsci12040052
pii:
doi:

Substances chimiques

Nitric Oxide 31C4KY9ESH
Smoke 0
Biomarkers 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Juan Silva-Gallardo (J)

Hospital General Regional 25, Mexican Social Security Institute, Mexico City 09100, Mexico.

Raúl H Sansores (RH)

Respiratory Department, Médica Sur Hospital, Mexico City 14050, Mexico.

Alejandra Ramírez-Venegas (A)

Tobacco and COPD Research Department, Ismael Cosío Villegas National Institute of Respiratory Diseases, Mexico City 14080, Mexico.

Robinson E Robles Hernández (RE)

Tobacco and COPD Research Department, Ismael Cosío Villegas National Institute of Respiratory Diseases, Mexico City 14080, Mexico.

Gustavo I Centeno-Saenz (GI)

Tobacco and COPD Research Department, Ismael Cosío Villegas National Institute of Respiratory Diseases, Mexico City 14080, Mexico.

Rafael J Hernández-Zenteno (RJ)

COPD and Bronchiectasis Clinic, Ismael Cosío Villegas National Institute of Respiratory Diseases, Mexico City 14080, Mexico.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH